UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 263

Sortiert nach

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

The New England journal of medicine, 2014-07, Vol.371 (2), p.130-139

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

Journal of dermatological science, 2019-05, Vol.94 (2), p.266-275

2019

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.400-409

2015

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Journal of the American Academy of Dermatology, 2017-01, Vol.76 (1), p.60-69.e9

2017

Link zum Volltext

Verfügbarkeit prüfen

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Frontiers in immunology, 2020-01, Vol.10, p.3096-3096

2020

Link zum Volltext

Verfügbarkeit prüfen

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2020-03, Vol.145 (3), p.877-884

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.729-735

2013

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.841-850

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Journal of the American Academy of Dermatology, 2017-08, Vol.77 (2), p.310-317.e1

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Journal of the American Academy of Dermatology, 2020-11, Vol.83 (5), p.1282-1293

2020

Link zum Volltext

Verfügbarkeit prüfen

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.377-388

2020

Link zum Volltext

Verfügbarkeit prüfen

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

Journal of Crohn's & colitis, 2016-03, Vol.10 (3), p.239-254

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

Journal of the American Academy of Dermatology, 2023-02, Vol.88 (2), p.395-403

2023

Link zum Volltext

Verfügbarkeit prüfen

IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid

Journal of autoimmunity, 2019-01, Vol.96, p.104-112

2019

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-12, Vol.75 (6), p.1162-1170.e3

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis

Rheumatology (Oxford, England), 2016-10, Vol.55 (10), p.1791-1795

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

The New England journal of medicine, 2018-10, Vol.379 (14), p.1313-1321

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

Drug safety, 2024-01, Vol.47 (1), p.39-57

2024

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

The Lancet (British edition), 2023-09, Vol.402 (10404), p.798-808

2023

Link zum Volltext

Verfügbarkeit prüfen

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

The New England journal of medicine, 2021-03, Vol.384 (12), p.1101-1112

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis

American journal of clinical dermatology, 2022, Vol.23 (Suppl 1), p.51-64

2022

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288

2017

Link zum Volltext

Verfügbarkeit prüfen

High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study

Modern rheumatology, 2022-01, Vol.ahead-of-print (ahead-of-print), p.1-9

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 263

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Full Collection 2018

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(231)

Publikationsform

Artikel
(259)
Berichte
(4)

Sprache

Englisch
(257)
Japanisch
(19)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study

Aktive Filter

Suchergebnisse filtern